PSFL2915

PSFL2915 is a **preclinical small-molecule P2X3 receptor inhibitor** reported in the scientific literature as an optimized analog derived from quercetin. It was described as a **nanomolar-affinity negative allosteric modulator** of the purinergic receptor **P2X3**, acting through an **inner pocket of the head domain** rather than the better-known P2X3 binding regions. In the cited 2023 *Nature Communications* study, PSFL2915 showed antitussive activity in mouse and guinea pig models and was presented as having efficacy comparable to gefapixant while potentially avoiding the taste disturbance associated with some P2X3-directed therapies. Publicly available evidence supports PSFL2915 as a research-stage therapeutic candidate for **refractory chronic cough** and related cough hypersensitivity settings, but there is no clear evidence from the provided context of clinical-stage development, assigned INN, or commercial manufacturing.